objective To develop a new PCR for Leishmania detection and to estimate its diagnostic accuracy in a visceral leishmaniasis (VL) endemic area.
Introduction
Visceral leishmaniasis (VL) is a potentially fatal vectorborne parasitic disease due to infection by Leishmania donovani in the Indian subcontinent and eastern Africa and by L. infantum in the Mediterranean basin, Central Asia and South America. The Indian subcontinent is one of the most affected regions and Nepal together with India and Bangladesh account for 70% of all reported deaths (Unicef 2006) . Diagnosis is currently based on antibody detection in blood with the direct agglutionation test (DAT) or rk39 dipstick, while antigen detection with the KATEX test in urine is still under evaluation (Boelaert et al. 2008 ). The disease is generally confirmed by microscopic demonstration of the parasite in bone marrow or spleen aspirates, requiring invasive sampling techniques. Sensitivity may be increased by prior in vitro cultivation of the parasite from these specimens but this is cumbersome and time-consuming.
Amplification of the parasite's DNA by the polymerase chain reaction (PCR) has evolved as one of the most specific and sensitive surrogate methods for parasite detection. Over the last two decades many PCR applications for detecting Leishmania have been reported (Antinori et al. 2007) . Attractive Leishmania genome target regions for PCR are high-copy sequences such as the small subunit ribosomal RNA (rRNA) gene (van Eys et al. 1992) , the kinetoplast DNA (Maurya et al. 2005) , or the spliced leader mini-exon gene (Reale et al. 1999) . Despite the wealth of existing PCR assays, very few have been sufficiently validated on a large number of clinical samples and none of them has become a reference tool in leishmaniasis diagnosis.
We here present a new PCR for Leishmania detection, targeting a short sequence within the 18S rRNA gene. After providing the proof-of-concept, we evaluated the PCR on experimental samples and on a large series of non-endemic controls. Finally, we estimated the diagnostic accuracy of the test on a consecutive series of blood and bone marrow samples from 299 patients suspected of VL recruited in Nepal between 2000 and 2002.
Materials and methods

Parasite
and from Trypanosoma brucei gambiense (MBA strain) and Trypanosoma cruzi (Y strain) was obtained from the DNA reference bank at the Institute of Tropical Medicine Antwerp (ITMA). DNA from Mycobacterium tuberculosis, Plasmodium falciparum and Schistosoma mansoni was obtained from other research groups.
Samples
The human experimentation guidelines of the ITMA were followed. Ethical clearance for the study was obtained from the institutional review boards in Nepal and Belgium.
Spiked blood
Leishmania donovani promastigotes were grown in GLSH medium (Le Ray 1975) with 10% foetal calf serum at 26°C. At day 3, post-inoculation, parasites were counted in a Bü rker counting chamber (Marienfeld, Germany) and 10-fold dilution series were made in human blood ranging from 10 000 to 1 parasite ⁄ 180 ll blood. Non-spiked blood was used as a negative control.
VL patients and endemic patient controls
Blood and bone marrow samples from clinically suspected VL cases were collected in the framework of a study conducted between 2000 and 2002 at the B.P. Koirala Institute of Health Sciences in Dharan, Nepal (Boelaert et al. 2004) . This study compared the diagnostic accuracy of 4 serological tests on 310 clinically suspected VL cases. Clinical suspicion for VL was defined as a history of fever for 2 weeks or more and splenomegaly. Bone marrow aspirates were analysed by microscopy and positive smears were scored from 1 to 6 according to the WHO classification (WHO 1990) . If the bone marrow aspirate was negative and malaria had been ruled out, a spleen aspirate was proposed. The DAT and rK39 dipstick were performed on the patient's serum in 2000-2002 as previously described. PCR analysis was performed in June 2007. The patient cohort was divided into three classes as follows: (i) confirmed VL patient if positive in parasite detection on bone marrow and ⁄ or spleen aspirate, (ii) probable VL patient if negative in parasite detection but seropositive in the rk39 dipstick and ⁄ or if DAT titre was 1:3 200 or more or when the patient showed positive response to sodium stibogluconate treatment and (iii) non-VL patient if negative in parasite detection; negative in rk39 dipstick and DAT titre was below 1:3 200 and therapeutic response was observed when other treatment than VL treatment was given. The HIV status was tested during the study between 2000 and 2002 for 303 patients who gave consent. Sera were screened with the HIV 1&2 Double Check (Orgenics Ltd., Israel) where after seropositive samples were confirmed using the INNO-LIA HIV I ⁄ II Score assay (Innogenetics, Ghent, Belgium).
Non-endemic controls
We defined VL non-endemic regions as regions where no active transmission of VL is reported. However, we cannot exclude sporadic autochthonous or imported cases in those areas. DNA extracts from blood of 19 healthy human Belgian blood donors, 25 confirmed T.b. gambiense infected persons from the Democratic Republic of the Congo and 230 confirmed P. falciparum infected persons from Benin (70), Burkina Faso (100) and Thailand (60) were obtained from the collection of the ITMA. All samples were anonymous. T.b. gambiense and P. falciparum infections were confirmed by direct parasite detection on blood.
DNA extraction from bone marrow and blood samples
Bone marrow aspirates were sent frozen to ITMA and DNA was extracted for further PCR analysis using the QIAamp DNA mini kit (Qiagen, Hilden, Germany). The 180 ll blood samples were stored in AS1 buffer (Qiagen), shipped to ITMA at ambient temperature and DNA was extracted with the QIAamp DNA blood mini kit. DNA extracts were stored at )20°C until PCR analysis.
Primers
Sequences of the 18S rRNA gene of the Trypanosomatidae parasites L. donovani (GenBank accession number X07773), T.b. gambiense (AJ009141) and T. cruzi (AF303660) were aligned and Leishmania primers were designed using the 'DNAman' software (Lynnon Corporation, Quebec, Canada). The sense primer 18S-L-F 5¢-CGTAGTTGAACTGTGGGCTGTGC-3¢ and the anti-sense primer 18S-L-R 5¢-ACTCCCGTGTTTCTT-GTTTCTTTGAA-3¢ amplify a 115 bp sequence within the 18S rRNA gene of Leishmania.
PCR amplification
The 50 ll reaction mixture contained 1 · Qiagen PCR buffer, 2.5 mM MgCl 2 (Qiagen), 200 lM of each dNTP (Roche, Mannheim, Germany), 0.8 lM of each primer (Sigma, Bornem, Belgium), 0.1 mg ⁄ ml acetylated bovine serum albumin (Promega, Madison, WS, USA), 1 U of HotStar Taq polymerase (Qiagen) and 5 ll of sample DNA. An initial denaturation step at 94°C for 15 min to activate the Hot Star Taq polymerase was followed by 40 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 30 s with a final extension at 72°C for 5 min. Amplification was conducted in 200 ll thin-wall PCR tubes (Abgene, Epsom, UK) in a T3 thermocycler 48 (Biometra, Gö ttingen, Germany). Amplified products were analysed by electrophoresis in a 2% agarose gel (Eurogentec, Seraing, Belgium) and U.V. illuminated (Syngene, Cambridge, UK) after ethidium bromide staining (Sigma, Bornem, Belgium).
Agreement PCR and DAT
The concordance between the PCR status and the DAT status was estimated using the kappa index. The PCR status was considered positive when a positive PCR result was observed on blood and ⁄ or bone marrow and negative when both blood and bone marrow were PCR negative. The DAT status was considered positive when the DAT titre was 1:3 200 or more.
Results
Analytical sensitivity
The detection limit of the PCR was evaluated on a tenfold serial dilution of L. donovani DNA in water containing 0.1 mg ⁄ ml acetylated BSA and on blood sample series spiked with decreasing numbers of living L. donovani promastigotes. The lower detection limits of the PCR were 10 fg DNA and 1 parasite ⁄ 180 ll blood (Figure 1 ).
Analytical specificity
The analytical specificity of the PCR was assessed with purified DNA from target Leishmania species and from relevant non-target parasites at a concentration of 1 ng per assay. The PCR amplified DNA from all Leishmania species tested, while no amplification was observed with DNA from P. falciparum, M. tuberculosis and S. mansoni. To verify the broad applicability of the PCR in other regions than Nepal we tested DNA from the closely related parasites T.b. gambiense and T. cruzi and no cross-reaction was observed.
Specificity on non-endemic control blood samples
The specificity of the PCR was evaluated on the 274 non-endemic control blood samples. One sample from Thailand was positive in the PCR thus yielding a specificity of 99.64% with a 95% confidence interval (CI) scored by Wilson's method (Wilson 1927 Figure 1 Analytical sensitivity of the 18S PCR on (a) a serial dilution of L. donovani DNA in water and (b) on a serial dilution of L. donovani promastigotes in naïve human blood. Lanes 1-10: 10 ng; 1 ng; 100 pg; 10 pg; 1 pg; 100 fg; 10 fg; 1 fg DNA per PCR, negative control for dilution, negative control for PCR. Lanes 11-16: 10 000; 1 000; 100; 10; 1; 0 parasites per 180 ll human blood. M: 100 bp DNA marker (Fermentas, St.Leon-Rot, Germany). Fourteen of the 303 patients tested for HIV infection showed a positive test result with the HIV 1&2 Double Check, of which four were confirmed with the INNO-LIA HIV I ⁄ II Score assay (one patient belonging to the probable VL group and three to the non-VL group). Three patients showed a doubtful positive test result with the HIV 1&2 Double Check but none were confirmed with the INNO-LIA HIV I ⁄ II Score assay.
Agreement between PCR and DAT
The PCR status of blood and bone marrow within each DAT titre group up to 1:204 800 is shown in Figure 2a . Of 131 patients with a positive DAT (titre ‡1:3 200) and for which PCR data on blood and ⁄ or bone marrow were available, 127 were positive in PCR while 38 of the 92 patients with a negative DAT were also negative in PCR (Figure 2b ). Thus we observed a concordance on positive status in 97% and on negative status in 41.3% with a kappa index of 0.416 (95% CI: 0.30-0.53) indicating moderate agreement. The same trend was observed when analysing the PCR results on blood and bone marrow separately (data not shown).
Discussion
We here report on the phases I and II evaluation of a new Leishmania PCR targeting a short sequence in the parasite's 18S rRNA gene. A shorter DNA fragment was amplified compared to the existing rRNA gene PCRs (van Eys et al. 1992) in order to (i) obtain higher PCR yield, (ii) shorten the elongation time during PCR and (iii) be able to transform the PCR into a simplified dipstick format, the Leishmania OligoC-TesT (Deborggraeve et al. in press) . The lower detection limits of the PCR are 10 fg of purified Leishmania DNA and one single parasite in 180 ll human blood. No cross reaction with DNA from non-target parasites was observed while all target species can be detected. Because of the high similarity of the primer target sequences, our PCR might give positive results in Endotrypanum and the monoxenous trypanosomatids Crithidia, Wallaceina and Leptomonas. While the chances of finding such protozoa in immune competent patients are negligible, they may present as opportunistic infections in immune compromised patients (Chicharro & Alvar 2003) . Furthermore, these trypanosomatids should be taken into account when testing wild animals and vectors (Arias et al. 1985; Dereure et al. 2001) . If needed, confirmation would be possible by direct sequencing of the PCR product since Leishmania possess a series of specific point mutations within the targeted region (data not shown). The sensitivity of our PCR was first evaluated on 173 confirmed VL patients, revealing a sensitivity of 92.1% on blood and 92.9% on bone marrow. The high sensitivity of the PCR on blood together with the observation that 94.5% of the patients with a positive PCR on bone marrow were also PCR positive on blood is encouraging. Indeed, this means that the molecular diagnosis on blood may be as sensitive as on invasive bone marrow aspirates. Leishmania donovani might be naturally more abundant in blood than L. infantum, thus favouring its anthroponotic transmission. The lack of a positive PCR result in some of the microscopically confirmed bone marrow aspirates can be due to inhibition during PCR, low parasite load given the low grades scored during microscopy and the delay between sample collection and PCR testing (up to 7 years). Furthermore, although usually deemed as 100% specific, false positive microscopic results due to staining artefacts cannot be excluded. Misclassification is most likely to occur in those specimens read as 'low parasite load'. Moreover, several cases in the probable VL group might be true VL cases, because of the suboptimal sensitivity of the reference test used. If all the probable VL are considered as true VL and added to the confirmed VL cases, we observed a significantly higher sensitivity of PCR on bone marrow compared to conventional microscopy (89% vs. 82.5%; Mc Nemar's test: P < 0.05).
The specificity of the PCR was first tested on 274 nonendemic control blood samples and 99.64% specificity was observed. The positive PCR result on one P. falciparum infected patient from Thailand might be due to a Leishmania infection since sporadic autochthonous VL cases have been reported in this country (Kongkaew et al. 2007) and since imported VL cases cannot be excluded. Secondly, the specificity was evaluated on Nepalese patients showing longstanding fever and splenomegaly but negative VL serology and microscopy and whose symptoms were attributed to another etiology. In this group of non-VL patients, Leishmania DNA was amplified in 38.2% of the blood samples and in 29.9% of the bone marrow samples. The high number of positive PCR results in the non-VL group is in fact not surprising, given the known high number of asymptomatic L. donovani carriers in endemic areas, which might develop febrile splenomegaly for other reasons. Though our PCR is not able to discriminate between infection and disease, quantitative real-time PCR might be helpful. Mary et al. (2004) observed a correlation between the parasite load and the clinical status of L. infantum infected persons by quantitative real-time PCR. A technological less complex alternative could be the combination of a very and a moderately sensitive PCR, as described by Lachaud et al. (2000) . Studying the concordance between PCR (DNA detection) and DAT (antibody detection), we observed a high concordance for a positive status and a low concordance for a negative status. In the DAT negative asymptomatic carriers the Leishmania infection is controlled mainly by the host's cell-mediated immune response. Four patients showed a positive HIV status of which three belonged to the non-VL group. Hence, negative DAT results for these three patients can be due to HIV co-infection.
Asymptomatic infections are currently not treated in VL endemic regions since the available drugs are very toxic and to avoid the raise and spread of resistant strains. Consequently, PCR provides a good marker for infection but may be of less value as a marker for acute clinical disease in VL endemic regions. However, immunodiagnosis faces the same limitations since a significant proportion of healthy individuals living in VL endemic regions have antiLeishmania antibodies in the blood (Sundar et al. 2006) . Therefore PCR and antibody detection test results should always be interpreted in combination with a standardized clinical VL case definition. Although its reported high sensitivity and specificity, PCR might currently not be able to compete with the immunodiagnostic tests due to the complexity of the technique and the lack of standardization. Efforts for simplification and standardization of PCR should therefore be strongly encouraged. At present, PCR can offer an added value compared to immunodiagnosis in HIV co-infected VL patients as well as in patient follow-up after treatment. Antibodies remain detectable for years after successful treatment (Hailu 1990 ) while the parasite's DNA is rapidly degraded following parasite death (Prina et al. 2007) . Finally, as it is potentially one of the best markers of Leishmania infection, further evaluation of the PCR as a tool for estimating prevalence and incidence of infection in epidemiological studies is recommended.
